Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

Recruiting

18-99 years

All

Phase 3

1000 participants needed

1 Location

Brief description of study

This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events (MACE) in subjects with Acute Coronary Syndrome (diagnosed with STEMI or NSTEMI), who are receiving evidence-based medical therapy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Acute Coronary Syndrome
Age: Between 18 Years - 99 Years
Gender: All

Male or Female, Age 18 or older, Evidence of myocardial necrosis, consistent with type I (spontaneous) MI

Updated on 09 Mar 2024. Study ID: 829891

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).